According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “
A number of other analysts also recently commented on ZEAL. Needham & Company LLC reiterated a buy rating and issued a $32.00 target price (up from $29.00) on shares of ZEALAND PHARMA/S in a report on Thursday, August 15th. Morgan Stanley raised their target price on shares of ZEALAND PHARMA/S from $29.00 to $30.00 and gave the stock an overweight rating in a report on Monday, August 19th. Finally, TheStreet lowered shares of ZEALAND PHARMA/S from a c rating to a d+ rating in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of Hold and an average price target of $27.33.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.10). The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $7.50 million. Sell-side analysts expect that ZEALAND PHARMA/S will post -2.22 EPS for the current year.
A hedge fund recently raised its stake in ZEALAND PHARMA/S stock. Farallon Capital Management LLC raised its position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) by 5.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,000,000 shares of the company’s stock after buying an additional 51,300 shares during the quarter. Farallon Capital Management LLC owned 3.25% of ZEALAND PHARMA/S worth $21,550,000 at the end of the most recent quarter. 9.38% of the stock is owned by institutional investors and hedge funds.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Featured Article: How does a margin account work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.